Skip to main content
ADPT
NASDAQ Life Sciences

CEO Chad Robins Sells $14.9M in Stock After Exercising Options

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$25.8
Mkt Cap
$4.068B
52W Low
$12
52W High
$26.16
52W Position info
115% above low
Off High info
1.4% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ADPT has more than doubled off its 52-week low of $12.

Summary

CEO Chad Robins exercised 600,000 options and sold all shares for $14.88 million, a significant insider sale near the stock's 52-week high.


Key Events · Ownership and Investor Activity · ADPT

  • CEO Sells $14.9M in Stock

    Chad Robins exercised 600,000 options at $6.55 and sold all shares for $14,882,166 at prices between $24.48 and $25.57 on August 17-18, 2026.

  • Sale Near 52-Week High

    The sale occurred with the stock trading near its 52-week high of $26.16, potentially locking in gains after a strong run.

  • Post-Transaction Holdings

    Robins retains 2,501,842 shares directly, indicating continued exposure despite the sale.

  • Recent Financing Context

    The sale follows a $345 million convertible note offering in June 2026, which may have influenced the timing of insider selling.


Analysis · ADPT · Life Sciences

CEO and Chairman Chad Robins exercised 600,000 options at $6.55 and immediately sold all shares for $14.88 million at prices between $24.48 and $25.57. The sale represents 0.46% of the company's market cap and comes as the stock trades near its 52-week high. While option exercises and sales are common for executives, the size and timing—following a strong Q2 and a $345 million convertible note offering—may draw investor attention.

How filings like this one have moved

In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADPT was trading at $25.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $12.00 to $26.16. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADPT - Latest Insights

ADPT
Aug 04, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $24.66
Real-time Price: $24.78 info
Change: +$0.1163 (+0.47%) info
Market Cap: $3.955B info
ADPT
Jul 29, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $22.15
Real-time Price: $24.78 info
Change: +$2.63 (+12%) info
Market Cap: $3.955B info
ADPT
Jul 29, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.59
Real-time Price: $24.78 info
Change: +$2.19 (+10%) info
Market Cap: $3.955B info
ADPT
Jul 01, 2026, 4:35 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $22.76
Real-time Price: $24.78 info
Change: +$2.02 (+9%) info
Market Cap: $3.955B info
ADPT
Jun 22, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $17.37
Real-time Price: $24.78 info
Change: +$7.41 (+43%) info
Market Cap: $3.955B info